2026 Sponsors

For more information please visit https://www.morganstanley.com/

BeyondSpring is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, in late-stage clinical development for NSCLC and other indications, acts as a dendritic cell maturation agent that supports both anti-cancer activity and immune modulation to resensitizing tumors resistant to checkpoint inhibitors.

Coherus Oncology is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies that potentially extend patient survival across tumor types. The approval of LOQTORZI® (toripalimab-tpzi) and the advancement of multiple clinical stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to immuno-oncology as a means for providing better treatment outcomes for patients.

Immunai's engineering-first platform maps the immune system to enable the discovery and augmentation of novel therapeutics through single-cell sequencing, functional genomics, big data, and machine learning. Immunai has a strong track record of partnering with leading pharmaceutical and biotech companies, academic institutions, and hospitals to optimize preclinical and clinical decision-making.

To learn more, please visit https://www.immunai.com/.

Lumanity is a global strategic partner for biopharmaceutical companies, engineering breakthrough value to transform lives. With 1,200 experts conducting work in over 50 countries, we combine scientific, clinical, regulatory, and commercial expertise with advanced technology to accelerate and optimize access to life-changing medicines. To learn more, please visit https://lumanity.com/

Onc.AI develops clinically validated, rigorously engineered deep-learning imaging biomarkers that predict treatment response and survival across immuno-oncology therapies. Global biopharma partners use Onc.AI’s patented models to strengthen early-phase decision-making and complement traditional imaging endpoints when assessing whether to advance or discontinue immuno-oncology programs.

Ozette transforms how scientists surface cytometry insights through our cloud native, vertically integrated analytical platform and our high-dimensional cytometry assays via Ozette Lab. Built for reproducibility, our platform accelerates biomarker identification and drug development, providing fast, transparent analyses that move teams from raw data to confident decisions with greater efficiency.

For more information, please visit: https://www.ozette.com/biological-insights/

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

TD2 Oncology is a global, science-driven CRO offering integrated preclinical, regulatory, and clinical services for oncology drug development. From IND strategy to global trial execution, we accelerate complex programs by reducing risk, streamlining timelines, and delivering specialized support from early development through approval.

Yunu is redefining how imaging powers clinical research. The company’s intelligent, end-to-end workflow platform streamlines every stage of imaging-based trials—from image capture and reader assignment to adjudication and data export—ensuring scientific integrity and operational efficiency. Trusted by life sciences, pharmaceutical, cancer centers, and research organizations worldwide, Yunu empowers teams to manage complex imaging studies with clarity, confidence, and speed.

ZEISS Microscopy empowers Biotech and Pharma industries with innovative imaging and workflow solutions for Tissue Multiplexing, 3D Human Tissue Models, and advanced Regulatory and Compliance workflow integration. Leveraging over 175 years of excellence in the fields of optics and optoelectronics, ZEISS combines cutting-edge microscopy solutions with expert Professional Services to enable accelerated discoveries, reproducible results, and regulatory readiness, helping you advance therapies and improve patient outcomes with confidence.

The Flywheel medical imaging platform empowers healthcare innovation by streamlining imaging data management, automating research workflows and preparing data for AI development. Scalable by design, Flywheel gives you tools to securely aggregate, annotate, curate and analyze large amounts of imaging and video data, either within your organization or with collaborators across the world.

MERIT is an oncology endpoint expert delivering image collection, centralized reading, and data management services for clinical trials since 2012. Through innovative and proven technologies, alongside our intuitive, seamless workflows, our experienced staff bring over a decade of clinical endpoint expertise, ensuring the integrity of your trials. Learn more: https://meritcro.com/oncology/

Nona Biosciences provides integrated solutions for antibody discovery and development. Using proprietary Harbour Mice® platforms that generate fully human H2L2 and HCAbs, we support diverse therapeutic formats. From immunization to IND-enabling services, our platforms and tailored solutions empower partners to move efficiently from idea to IND with flexibility and confidence. 

OCCAM Immune is a non-profit Academic Research Organization emerging from Mount Sinai Hospital that provides immune monitoring services for clinical trials. Its streamlined process, from contracting to data delivery, and its one-stop shop approach—from sample processing to assays and data analysis—bridge academic research excellence with industrial scalability. For more information, go to https://occam-immune.com/

PredxBio, a TechBio company headquartered in Pittsburgh, is powering next-generation cancer therapeutics with its AI-driven spatial biomarkers, which delve into the mechanism of action of drugs and predict patient outcomes with over 90% accuracy. By transforming multiplexed biopsy images and multi-modal spatial data into actionable insights and revealing the network biology of cancer, PredxBio's SpaceIQ platform is setting new standards for biomarker discovery and clinical research. Partnering with top pharmaceutical companies, PredxBio is accelerating drug discovery and advancing personalized medicine to impact over 25 million cancer patients globally. For more information, visit www.predxbio.com.

RadMD is a global Imaging Clinical Research Organization (iCRO) providing comprehensive imaging services for clinical trials from Phase 1 to Phase 4 for pharmaceutical and biotech companies as well as CROs. Supporting sites in over 70 countries and a network of 300+ subspecialty-trained radiologists and imaging experts, RadMD delivers consistent, compliant and high-quality imaging solutions.  For more information, visit https://radmdimaging.com

MedQIA, WorldCare Clinical, and DARC have come together to form Voiant, the industry’s leading clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise. Voiant’s purpose-built AI-powered platform Voiant Hub integrates all aspects of clinical trial imaging, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data.

GenoBioTX develops advanced genetically engineered animal models, offering 15,000+ catalog strains, 1,000+ humanized models along with 19,000+ custom models for drug discovery. GenoBioTX also provides pre-clinical CRO and fully human antibody development services across multiple disease areas, with a focus on immuno-oncology. For more information, visit genobiotx.com.

Picture Health develops interpretable, novel AI imaging biomarkers that characterize tumor biology from routine medical images. QVT™ is the first and only biomarker to directly measure tumor vascularity and angiogenesis from standard-of-care radiology available for all patients in active or completed clinical trials. Built on our Px™ Platform, these next-generation standard or custom radiomics and pathomics biomarkers enable biopharma partners to improve patient characterization, understand the mechanism-of-action, and accelerate decision-making through clinical trial deployment. early-phase oncology trials. For more information, please visit https://picturehealth.com/

radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information, go to www.radiomics.bio

RareCyte provides Precision Biology™ products and services for discovery, translational research and clinical diagnostics. The Orion™ spatial biology platform enables whole-slide highly multiplexed tissue analysis for multiple samples per day. Comprehensive liquid biopsy offerings enable CTC and other rare cell characterization and single cell retrieval for molecular analysis and CDx development. For more information, go to https://rarecyte.com/

Backed by our brilliant minds, we have turned the traditional CRO model on its head, by fostering a collaborative and personalised approach. Our mission is simple: Solve problems. Deliver quality data. Propel your drug discovery breakthroughs. United by a passion to make sense of complexities and overcome challenges, we apply our specialised knowledge to big-picture thinking. We will explore every option to deliver over and above for your project. We are thought leaders with a deep understanding of immunology, bioassays, molecular biology and a track record of groundbreaking discoveries and novel cell-based tools. For more information, visit https://rouken.bio/

7 Hills Pharma’s proven management team is advancing first-in-class selective integrin activators leveraging a unique MoA to improve cancer immunotherapy efficacy without increasing side effects.

Abalos is a clinical stage company. We develop a truly novel approach to overcome cancer immunotherapy hurdles based on a multi-modal mechanism of action.

Liberate Bio merges real in vivo biology with AI to design next-generation nanoparticles that selectively reprogram immune and other cell types—expanding genetic medicine far beyond the liver.

OncoPrecision is a next-generation oncology therapeutics company leveraging large-scale, patient-derived biology and AI-enhanced discovery platforms to develop precision medicines with higher probability of clinical success.

Vizenpistat (SR-8541!A), a new revolutionary cancer therapy, is a first checkpoint inhibitor for innate immunity restoration, needed in ½ of all cancers, in Ph2 clinicals.

For more information please visit https://www.syenex.com/

TATUM Bioscience is redefining cancer treatment with multi-specific nanofilament immunotherapy. Our breakthrough technology boosts tumor visibility, restores immune function, and drives lasting antitumor responses—positioning TATUM at the forefront of next-generation immuno-oncology.

Virogin Biotech is a clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virus (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Both the platforms exhibit a high degree of complementarity via a mechanism of heterologous prime-boost. Enhanced anti-tumor efficacy has been observed if OV and mRNA tumor vaccines were combined due to (1) modulation of immune-suppressive tumor microenvironment through release of immunological payloads carried by OV, and (2) antigen spread via direct tumor cell lysis triggered by OV infection, which functions like an in situ personalized tumor vaccine. Yet each platform has ‘plug-to-play' features to independently develop novel therapies against cancer & other indications. Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.